Skip directly to content

Dutch home

MISSION

Pfizer is strongly committed to research in the Inflammation area and supports medical innovation in The Netherlands through this Competitive Investigator Research Award Program.

The Dutch ASPIRE Inflammation Competitive Research Program (I-CRP) aims to inspire and fund innovative research projects in the field of inflammation which may further enhance the understanding of certain rheumatology, dermatology and gastroenterology conditions and contribute to excellence in patient care.

An independent external review committee of European medical experts in the field of Inflammation will review the research proposals and select the grant recipients.

This program provides research grants for studies designed and conducted by non-Pfizer physicians and scientists.

REQUEST FOR PROPOSALS

Pfizer invites investigators to apply for the Dutch ASPIRE I-CRP through submission of research proposals with the primary objective to further enhance the understanding of certain therapeutic areas and contribute to excellence in patient care.

  • It is anticipated that individual awards up to €30.000 will be made. Funding will be spread over the lifetime of the project
  • The grants will be non-renewable and will be for research to be undertaken within a time period of a maximum of 12-18 months
  • Due to the competitive nature of the awards, Pfizer cannot provide any additional funding and/or drug support beyond what has been requested and approved by the external review panel
  • The deadline for submission is June 1th at 24.00 CET

AREAS OF FOCUS

For 2017, applications in the following high interest areas will be considered:


Rheumatoid Arthritis (RA)

  • Adherence to treatment
  • Co-morbidities
  • Disease management strategies
  • Mono therapy
  • Patient reported outcomes
  • Predicting response to treatment
  • Treatment monitoring (role of imaging)
  • Unmet medical needs (eg pain, fatigue)
  • Value of therapy


Psoriatic Arthritis (PsA)

  • Adherence to treatment
  • Axial disease in PsA
  • Co-morbidities
  • Disease management strategies
  • Early diagnosis (imaging in) and treatment
  • Imaging in early diagnosis
  • Mono therapy
  • Predicting response to treatment
  • Treatment monitoring
  • Unmet medical needs (eg pain, fatigue)
  • Value of therapy


Colitis Ulcerosa (CU)

  • Adherence to treatment
  • Co-morbidities
  • Disease management strategies
  • Early diagnosis and treatment
  • Mono therapy
  • Patient reported outcomes
  • Predicting response to treatment
  • Treatment monitoring
  • Unmet medical needs (eg pain, fatigue)
  • Value of therapy

INDEPENDENT EXTERNAL REVIEW COMMITTEE

The Dutch ASPIRE I-CRP applications will be reviewed by an independent, external review committee compromised of medical and scientific experts. The independent, external review committee will evaluate all proposals and select those to be awarded. Titles of the awarded projects and names of investigators will be made public through this web page. .

AVAILABLE AWARDS

Pfizer is funding awards up to €30.000 each for a time period of 12-18 months. It is expected that the results will be presented at scientific meetings and published in peer reviewed journals.

DEADLINE FOR APPLICATION AND KEY DATES

  • Application submission start: Mar 15 2017
  • Application deadline: Jun 1 2017, 24.00 hrs
  • Applications reviewed by commission: July 2017
  • Awards announcement: Sep 2017
  • Research period: Dec 2017 onwards